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Background: With high morbidity, mortality and disability rate, brain infarction brings a huge economic and health
burden to the whole society in China. Although some previous studies suggested that telerehabilitation may
facilitate rehabilitation for stroke survivors at home, the evidence is insufficient for clinical application; additionally,
as yet no trial evaluates efficacy of telerehabilitation for brain infarction patients. Therefore, more high quality trials
are needed to provide practice evidence for this novel rehabilitation strategy.
Methods/Design: Based on recruitment criteria, this assessor blinded, paralleled randomized controlled trial will
recruit 210 brain infarction patients. After being randomly allocated into two groups, participants will receive
home-based tele-supervising rehabilitation or conventional rehabilitation. Outcome measurement will be conducted
at the end of intervention and 90-day follow-up. Among which, Barthel index assessment will be considered as primary
outcome measurement, secondary outcome measurements include NIHSS score, mRS score, 3-oz water swallow test
and surface electromyography. Adverse events will also be recorded during the whole process of the trial for safety
assessment.
Discussion: The HTRBIP trial will evaluate efficacy and safety of home-based tele-supervising rehabilitation for
brain infarction patients. It is expected to provide new evidence for telerehabilitation application.
Trial registration: Registration date: 17 September 2014; Registration number: ChiCTR-TRC-14005233
Keywords: Brain infarction, Stroke, Rehabilitation, Telemedicine, TelerehabilitationBackground
In China, there are 2.5 million new stroke patients each
year and stroke has become a leading cause of adult death
and disability [1-3]. It is estimated that stroke care annu-
ally costs nearly 40 billion RMB (6.35 billion US dollars)
in China, which brings a huge health burden to the society
[2]. Among different stroke types, the incidence of brain
infarction is approximately twice that of hemorrhagic
stroke; therefore, brain infarction may be a key element
for solving the problem caused by stroke [4].
Although recombinant tissue plasminogen activator
(rt-PA) has been approved as the fundamental therapy* Correspondence: renchuancheng@outlook.com
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unless otherwise stated.for thrombolysis, because of its utilization restrictions,
the thrombolytic rate is still low [5,6]. Based on the re-
port of the Chinese National Stroke Registry (CNSR),
the rate of administration of intravenous rt-PA rate for
acute brain infarction patients in China is merely 1.6%
[7]; and more than half the survivors are frustrated by
physical deficiency after discharge from hospital, which
limits their daily activity and poses a heavy burden on
their families [8]. Numerous clinical trials have demon-
strated that physical rehabilitation can ameliorate neuro-
logical functional impairment and raise quality of life
[9,10]. However, because of transportation restrictions
and high costs, most brain infarction survivors in China
cannot receive professional supervised rehabilitation,
which restricts physical function recovery and delays
the best rehabilitation time [11]. To resolve the problem,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Telerehabilitation, which was first reported in late
1990s, can be defined as an alternative method for deliv-
ering rehabilitation services via a certain telecommuni-
cation system [12]. This novel rehabilitation strategy
facilitates brain infarction survivors receiving long-term
ongoing rehabilitation with supervision, especially for
those who reside in remote areas and have hardly any
access to rehabilitation expertise [13,14]. After being first
reported in the late 1990s, telerehabilitation aroused
wide interest. Several randomized controlled trials have
demonstrated that compared with conventional rehabili-
tation care, telerehabilitation can improve physical func-
tion under remote guidance through a tele-consultant
[15-17]. It also indicates that there are no differences
between telerehabilitation and usual rehabilitation in
patients’ satisfaction, comprehension of treatment, user-
friendliness, and the patient-therapist relationship [18,19];
moreover, it may also reduce travel time, being more con-
venient for patients receiving rehabilitation guidance.
Therefore, it seems that telerehabilitation can successfully
encourage patients to persist with rehabilitation treatment
and improve their physical function recovery.
Despite its advantages, clinical application for telerehabil-
itation is still limited. Based on a recent Cochrane study,
more randomized controlled trials (RCTs) are needed to
supplement clinical evidence for telerehabilitation applica-
tion [20]. And because there is no clinical trial to evaluate
telerehabilitation for brain infarction patients, our group
will conduct an assessor blinded, randomized, paralleled
controlled trial to investigate efficacy and safety of home-
based tele-supervising rehabilitation for brain infarction
patients, and further increase the experience gained from
this novel rehabilitation strategy application.
Methods and design
Study objective
The main objective of the home-based tele-supervising
rehabilitation for brain infarction patients (HTRBIP) trial
is to investigate the efficacy and safety of home-based
tele-supervising rehabilitation for patients after brain in-
farction. The specific study objectives are:
1. Primary research question: compared with
conventional rehabilitation care, will home-based
tele-supervising rehabilitation improve daily living
activity of brain infarction patients at the end of 90
or 180 days after intervention has been initiated?
2. Secondary research question: compared with
conventional rehabilitation care, will home-based
tele-supervising rehabilitation improve neurological
function of brain infarction patients at the end of 90
or 180 days after intervention has been initiated?3. Record physiological data and adverse events to
investigate safety of home-based tele-supervising
rehabilitation for brain infarction patients.
Study design
The HTRBIP trial is an assessor blinded, paralleled RCT.
Participants will be recruited in Shanghai Number 5
Hospital, Fudan University, Shanghai, China. After
signing informed consents, eligible patients will receive
baseline assessment, and then be randomized into the
tele-supervising rehabilitation group or conventional
rehabilitation group. Participants in both groups will
receive rehabilitation intervention for 90 days; specific
rehabilitation strategy in each group will correspond to
the allocation. At the end of intervention and 90-day
follow-up, a group of assessors blinded to allocation and
intervention will measure the outcome. Meanwhile, adverse
events will be recorded during the whole process of the
trial. Figure 1 depicts simply the study design, and Table 1
shows the trial procedure.
Participant recruitment
Participant recruitment will be conducted in Shanghai
Number 5 Hospital, Fudan University, Shanghai. Before
discharge from hospital, each brain infarction patient
will be identified by two independent neurologists ac-
cording to inclusion and exclusion criteria. After being
confirmed, eligible patients will receive a face-to-face
meeting for exchanging the information of the study. If
eligible patients accept and decide to participate in the
study, they will be asked to sign the informed consent and
follow the subsequent study process, which includes base-
line assessment, randomized allocation, intervention receiv-
ing, and follow-up visiting. Informed consent from each
participant should be obtained before baseline assessments.
Sample measurement
Primary outcome of the study will be measured by using
the Barthel index. The main purpose of the study is to
investigate the efficacy of tele-supervising rehabilitation
compared with conventional rehabilitation, and sample
size calculation will be conducted by following formula:
n1 ¼ n2 ¼




According to the previous study, difference in means
of 90-day post-stroke Barthel index is 7.8 and standard
deviation is 18.35 [21]. Taking 5% 2-side significance
level and 80% power into consideration, at least 87
participants need to be recruited in each group. For 20%
attrition, our study will recruit 105 participants in each
group.
Figure 1 Flow chart illustrating the home-based tele-supervising rehabilitation for brain infarction patients (HTRBIP) trial design.
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Patients will be eligible for inclusion if they meet all the
following criteria: 1) be aged 35 to 85 years old, male or
female; 2) be first diagnosed as brain infarction or have
historical brain infarction but without neurological func-
tion impairment; 3) be 14 to 90 days from brain infarc-
tion onset; 4) have National Institute of Health StrokeScale (NIHSS) scores from 2 to 20, modified Rankin
Scale (mRS) scores from 1 to 4; 5) have not previously
received any rehabilitation intervention.
Exclusion criteria
Patients will be excluded if they meet any of following
criteria: 1) have Glasgow Coma Scale (GSC) scores under







Time 4c: at the end
of intervention
Time 5d: 90- day
follow-up
Informed consent obtained √
Epidemic data collection √
Medical history collection √
Physical examination √




Body temperature √ √
Respiratory rate √ √
Pulse rate √ √
Blood pressure √ √




Primary outcome measurement (Barthel index) √ √ √
Secondary outcome
measurement
NIHSS score √ √ √
mRS score √ √ √
3-oz water swallow test √ √ √
sEMG √ √ √
Adverse events record √ √ √ √
aTime 1: 2 to 7 days before intervention initiation.bTime 2: 0 to 2 days before intervention initiation.cTime 4: 90 days after intervention initiation.dTime 5: 180 days
after intervention initiation.
Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sEMG, surface electromyography.
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Minimum Mental State Examination (MMSE) assessment,
with mental disorders and unable to cooperate with
examination, treatment or follow-up; 2) have disability
not induced by brain infarction or disability induced
by historical brain infarction; 3) have associated severe
primary disease of heart, liver, kidney or hematological
system; 4) have cognitive disorder, history of psychosis,
substance abuse or alcoholism; 5) have skin infections in
the antebrachium or crus; 6) have associated hemorrhagic
or skin ulceration tendency; 7) have metal implants in the
body, including cardiac pacemaker, metal stent or steel
plate; 8) be in the gestation or lactation period or have a
fertility plan; 9) have associated malignant tumor or severe
progressive disease in any other system; 10) have been re-
cruited by any other clinical trial in the preceding 90 days;
11) be unable to complete the basic course of treatment,
with poor treatment adherence or inability to follow-up;
12) have other conditions that render them unable to con-
tinue the trial.
Randomization and allocation concealment
After being recruited and having undergone baseline
assessment, participants will be randomly allocated into
either tele-supervising rehabilitation or conventional re-
habilitation. Block randomization will be stratified by age(≤65 years old, > 65 years old) and NIHSS score (2 to 10,
11 to 20) with 1:1 allocation to each group. An independ-
ent statistician will conduct randomized allocation by
using a computer. Allocation concealment will be ensured,
as allocation information will be protected in opaque
sealed envelopes by a specified staff member who is not
involved in the study. Only after participant recruitment
and baseline measurements are completed, will the enve-
lopes be opened.
Blinding
Because tele-supervising rehabilitation needs the use of
a specific device for computer-based tele-consultation, it
is impossible to blind the patients and tele-supervising
rehabilitation therapists to allocation and intervention.
In order to reduce bias, outcome assessment and data
analysis will be carried out by an independent neurolo-
gist and a statistician respectively; both of them are
blinded to allocation, baseline measurements, and re-
habilitation intervention.
Intervention
Participants in both groups will receive physical exercise
and neuromuscular electrical stimulation after dischar-
ging form hospital. Physical exercise will be conducted
for 2 hours per day following the principle of the Bobath
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turning movement, and bridge movement. Neuromuscular
electrical stimulation will be conducted by using a portable
muscle electricity biofeedback instrument (MyoNet-COW;
NCC Electronic Co. Ltd, Shanghai, China) for 30 minutes
per day. Both physical exercise and neuromuscular electrical
stimulation will be carried out by trained therapists follow-
ing the standard operation procedure guidance.
Tele-supervising rehabilitation group
Under the guidance of trained therapists and with the
help of caregivers, participants in the tele-supervising
rehabilitation group will receive rehabilitation therapy
at their home via using a telerehabilitation system
(Figure 2). The telerehabilitation system consists of
three parts: a doctor work platform, a patient platform
and a proprietary network system. The network sys-
tem provides sufficient bandwidth for remote diagno-
sis, treatment and data collection. The doctor work
platform is composed of a high-quality video/audio
system, electronic medical records system and remote
control system. Therapists can obtain the medical
history information from electronic medical records,
guide the participants to do the physical exercise and
neuromuscular electrical stimulation by the high-quality
video/audio system, and collect data by the remote control
system during rehabilitation therapy. The patient plat-
form will be implemented at participants’ homes after
randomization allocation, which includes the high-quality
video/audio system, physiological data collection system
and muscle electricity biofeedback instrument. Partici-
pants or their caregivers will receive rehabilitation guid-
ance from therapists via the high-quality video/audio
system. Electricity biofeedback instrument will provide
neuromuscular electrical simulation to the participants
and collect surface electromyography (sEMG). Physio-
logical data collection system (NTH-M6; NCC Electronic
Co. Ltd, Shanghai, China) will record body temperature,
respiratory rate, pulse rate, blood pressure, surface electro-
cardiogram, and peripheral blood oxygen saturation
during the process of therapy. These physiological dataFigure 2 Schematic diagram of home-based tele-supervising rehabilitwill be feedback to the doctor platform for supervision by
the therapists. Each participant will receive rehabilitation
therapy once per day.
Conventional rehabilitation group
Participants in the conventional rehabilitation group will
receive rehabilitation therapy once per day in the out-
patient department of Shanghai Number 5 Hospital,
Fudan University. The therapeutic strategy is the same
as the tele-supervising rehabilitation group except for
using the telerehabilitation system. Physical exercise and
neuromuscular electrical stimulation will be carried out
face-to-face by a trained therapist at the bedside. Besides,
the equipment model of the muscle electricity biofeedback
instrument and physiological data collect system are the
same as used in the tele-supervising rehabilitation group.
Data measurement
Data measurement will be carried out by trained inde-
pendent assessors, who are blinded to allocation and
intervention, and who will be required to be prevented
from learning allocation or intervention information
from patients during outcome measurements. Baseline
data assessment will be carried out in hospital before
randomization allocation. In order to keep allocation
and intervention from assessors, outcome measurements
will be conducted at the neurology outpatient depart-
ment at the end of intervention and 90-day follow-up.
A specified trial staff member will make an appointment
with patients the day before outcome measurements and
will make suggestion about the next day’s physical exam-
ination including not to provide treatment information to
the physician.
Baseline assessment
Baseline assessment consists of epidemiologic data
(including age, gender, history of present complaint,
past medical history, physical examination, and auxil-
iary examination); NIHSS score, Barthel index score,
mRS score, water swallow test, and sEMG. Meanwhile,
physiological data will also be measured, which includesation.
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sure, surface electrocardiogram, and peripheral blood oxy-
gen saturation.
Primary outcome measurement
Primary outcome measurement will be conducted by
using the Barthel index at the end of intervention and
90-day follow-up. The Barthel index consists of ten
items: presence or absence of fecal incontinence, pres-
ence or absence of urinary incontinence, help needed
with grooming, toilet use, feeding, transfers, walking,
climbing stairs, bathing and dressing. The score ranges
from 0 to 100, with high scores demonstrating high
activities of daily living [22,23].
Secondary outcome measurement
Secondary outcome measurement, which includes NIHSS
score, mRS score, 3-oz water swallow test and sEMG, will
be carried out at the same time with the primary outcome
measurement.
Neurological function deficient will be measured by
NIHSS score; it has been confirmed as a widely used
scale with high reliability and good convergent validity.
NIHSS includes 11 items, ranging from 0 to 42, with
low scores depicting good neurological function [24,25].
General disability condition will be measured by mRS
score, which consists of 6 ranks: rank 0 demonstrates no
disability symptoms; rank 1 demonstrates no significant
disability, despite with symptoms, able to perform all
usual duties and activities; rank 2 demonstrates slight
disability, although with the ability to look after own
affairs without assistance, but be unable to carry out all
previous activities; rank 3 means moderate disability,
requiring some help in daily life, but with the ability to
walk without assistance; rank 4 means moderately severe
disability, with the inability to walk without assistance
and attend to own bodily needs without assistance; rank
5 means severe disability, depicts patients who are bed-
ridden, incontinent or require constant nursing care;
rank 6 equates to death [26,27].
Swallowing function and the presence of dysphagia
will be measured by the 3-oz water swallow test [28].
Participants will be asked to drink 3 oz of warm water
without interruption. Criteria for assessment of swallow-
ing includes being unable to complete the task, coughing,
choking, or with a wet-hoarse vocal quality exhibited
either during or within 1 minute of test completion.
Compared with other bedside assessment, the 3-oz water
swallow test has high specificity and sensitivity in detect-
ing aspiration in dysphagia patients after stroke [29].
As motor unit recruitment is crucial for evaluating
muscle activity after brain infarction, sEMG will be
employed to monitor the root mean-squared (RMS)
value of target body regions. RMS value of the sEMGsignals reflects the association of muscle activity with
motor unit recruitment [30].
Adverse events
Although therapeutic treatment will be conducted with
the guidance of trained therapists, and the intervention
strategy of the study is low risk, it is impossible to ignore
adverse event measurement. Therefore, all the partici-
pants as well as their caregivers and research team staff
will be asked to report adverse events. Besides, physio-
logical data will be recorded to assess the physical condi-
tion of the participants during intervention. A group of
research staff will be trained to record and analyze
physiological data and deal with adverse events. If severe
adverse events happen, the group will report the events
to the study director and quality control committee and
the study will be suspended if necessary. Once the study
has to be suspended because of severe adverse events,
only when the severe adverse events can be successfully
prevented, can the suspended study be recommenced.
Quality control
The study has been registered in the Chinese Clinical
Trial Registry (ChiCTR) and supervised by the superior
authority. A Quality Control Committee will be estab-
lished before trial initiation, and will consist of six members,
including two neurologists, two rehabilitation specialties,
and two statisticians. The committee will help the research
team write the trial protocol and standard operation proced-
ure, supervise the whole process of the study, and control
the quality. The research team will receive specific training
for standardizing the procedure of the entire study including
participant recruitment, therapeutic intervention, outcome
measurement and data analysis. Additionally, all the data
should be checked according to the standard operation pro-
cedure of the study at least once per week during the study
process.
Statistics
An independent statistician, who is blind to allocation
and intervention, will take charge of data analysis. All
the variables will be analyzed according to an intent-to-
treat (ITT) basis, and the statistical tests will be 2-side
and at the 5% significance level. All the participants
under randomization will be included in the analysis, re-
gardless of whether or not they adhered to the treatment
or provided complete data sets. For providing valid in-
ferences with less restrictive assumptions, multiple im-
putation will be performed to analyze missing data.
Continuous variables will be summarized by means and
standard deviation. The normality of the distribution will
be checked before comparison by using the Shapiro-Wilk
test. Normally distributed variables will be compared by
using the t-test, and the Mann-Whitney U-test will be
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Discrete variables will be summarized by relative frequen-
cies and analyzed by using a non-parametric test. The
level of statistical significance will be set at P < 0.05. SAS
V9.1 (SAS Institute, Cary, NC, USA) will be employed for
all the statistical analysis. The statistical analysis plan will
be fully specified and approved before unmasking.
Ethics
The HTRBIP trial follows the Helsinki Declaration and has
been approved by the Independence Ethics Committee of
the Fifth Peoples’ Hospital of Shanghai, Fudan University
(ethic approval number: 2014-ETRE-066). Participants will
be acquainted with informed consent and asked to sign for
it before being recruited.
Dissemination policy
The HTRBIP trial study and results will be published in
peer-reviewed journals in line with the reporting guide-
lines; namely, TIDieR for description of interventions
and the Consolidated Standards of Reporting Trials
(CONSORT) extension for non-pharmacological drugs.
Trial results will be submitted to the trial registry, and
will be communicated to participants via written and
oral reports. The results will also be reported to local
policy-makers (Shanghai Municipal Commission of Econ-
omy and Informatization, Shanghai Municipal Commission
of Health and Family Planning). Additional stakeholders,
including telerehabilitation device manufacturers and net-
work service corporations, will be informed of the trial
findings. Trial results will be disseminated regardless of the
magnitude or direction of effect.
Discussion
Stroke is the leading cause of adult death and disability
in China, and brain infarction is its majority component.
Since over 50% of brain infarction patients are still suf-
fering from physical disabilities after discharge from hos-
pital [20], and because most brain infarction survivors in
China used to conduct rehabilitation at home, a novel
rehabilitation strategy is needed to facilitate rehabilitation
in patients’ residences under professional supervision.
Home-based telerehabilitation, which utilizes informa-
tion and communication technology to connect patients
and therapists, is considered as a potential solution for
poor rehabilitation outcome of brain infarction patients
after discharging from hospital [31,32]. Some research
groups conduct clinical trials to investigate the feasibility
of home-based physical rehabilitation. To date, there are
ten RCTs investigating post-stroke telerehabilitation [20].
However, because of small sample size, significant hetero-
geneity and high risk bias; these previous RCTs could not
conclude the practical guidance for post-stroke telereh-
abilitation application; thus, more adequately poweredstudies are required. Additionally, because there are cur-
rently no clinical trials evaluating the effectiveness of tele-
rehabilitation for brain infarction patients worldwide, it is
reasonable for us to conduct this clinical trial to provide
new evidence for home-based tele-supervising rehabilita-
tion application.
The HTRBIP trial is designed as an assessor blinded,
paralleled RCT. Tele-supervising rehabilitation will be
conducted through a specialized system that can con-
nect therapist and patient over distance; data collecting
will be simultaneously performed during rehabilitation.
Barthel index at the end of intervention and at 90-day
follow-up will be evaluated as primary outcome meas-
urement, which represents the general physical function
for disabled patients after brain infarction. NIHSS score,
mRS score, 3-oz water swallow test and sEMG will be
employed for secondary outcome measurement. Further-
more, adverse events will be recorded for safety evaluation.
For tele-supervising rehabilitation specialized remote inter-
action devices are required, and because it is impossible to
blind the intervention strategy to the patients and thera-
pists, this trial could not be double-blinded. To make up
for this limitation and ensure the quality of the trial,
outcome assessors and data statisticians will be blind
to the allocation and intervention strategy.
The HTRBIP trial will evaluate efficacy and safety of
home-based tele-supervising rehabilitation for brain in-
farction survivors in China, which is expected to supple-
ment evidence for telerehabilitation application, and
increase the experience gained for its practice.
Trial status
Recruitment has begun as of September 2014.
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